(RTTNews) - Nektar Therapeutics (NKTR), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata, a chronic, systemic, immune-mediated inflammatory disease.
Notably, findings from several clinical trials have demonstrated that rezpegaldesleukin safely and dose-dependently increased regulatory T cells.
The company is on track to announce topline data in December from its ongoing REZOLVE-AA Phase 2b study, involving patients with severe-to-very severe alopecia areata.
Moreover, the biotechnology company expects to collaborate with the FDA on a potential registrational program following the completion of Phase 2.
Currently, NKTR is trading at $23.55, down 0.42 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
